Ischemix, Inc. Receives US Department of Defense Funding of $2.9 million to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury (TBI)

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement